Labcorp, based in the US, has announced the expansion of its global offerings and its footprint in the Asia-Pacific (APAC) region with the opening of a new, integrated bioanalytical laboratory in Singapore.

The laboratory features new capabilities that enhance the substantial array of bioanalytical services currently offered through Labcorp Drug Development, allowing the company to meet increased demand from pharmaceutical and biotechnology companies.

"Singapore serves as a strategic location from which Labcorp can increase accessibility by offering regional and international clients comprehensive support for their bioanalytical studies," said Dr. Paul Kirchgraber, CEO of Labcorp Drug Development. 

The integrated bioanalytical laboratory will be co-located with Labcorp's Central Laboratory Services and Clinical Development and Commercialization Services segments, bolstering the company's laboratory network in APAC.

By expanding its bioanalytical capabilities in Singapore, Labcorp advances its regulated and non-regulated services and further supports the development of small and large molecule studies. The new, integrated laboratory will also offer Good Laboratory Practice (GLP)- and Good Clinical Practice (GCP)-compliant bioanalysis, liquid chromatography-mass spectrometry and immunochemistry platforms, as well as clinical biomarker analytical services.